Abstract
Purpose: :
The inhibition of RPE proliferation by chemotherapeutic agents remains a primary target in the treatment of PVR. In this study, we investigate the effect of some commercially available topoisomerase inhibitors on the RPE cells.
Methods: :
Study medications included topotecan, etoposide, doxorubicin, and daunorubicin at various concentrations (100, 50, 30, 10, 1, 0.1, 0.01 ug/ml). Rabbit RPE cells were used. After 48 and 96 hours, MTT assay and cell counting were used to determine cell survival and proliferation rate.
Results: :
Four drugs all inhibited proliferation of RPE cells in a dose–dependent manner in vitro. The actual numbers of cells correlated well with the results of the MTT test. The IC50 is defined as the concentration of a drug that produces a 50% reduction in cell number. The IC50 of topotecan, etoposide, doxorubicin, and daunorubicin was 0.1–1, 1–10, <0.1, and <0.1 ug/ml respectively at 48hours. The slope of dose–response curve was slowly declined for topotecan and etoposide, but very sharp for doxorubicin and daunorubicin.
Conclusions: :
Topotecan and etoposide have both effective and safe property as RPE cells inhibitors.
Keywords: proliferative vitreoretinopathy • retinal pigment epithelium